Radius Health, Inc. RDUS announced positive top-line data from the phase III ATOM study which is evaluating its lead product, Tymlos (abaloparatide 80 mg subcutaneous [“SC”]) injection, for use in men ...
TYMLOS ® demonstrated a lower incidence of hip fracture and non-vertebral fracture compared to teriparatide in women with osteoporosis 50 years and older (n=43,352) in this analysis of real-world data ...
Analysts expected Eli Lilly’s Forteo to be the big challenge standing in the way of new Radius bone drug Tymlos. But Express Scripts apparently has other ideas. On Monday, the PBM giant said Forteo ...
Labatec Pharma SA: Switzerland and the MENA region including Bahrain, Iraq, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, UAE, Algeria, and Morocco Pharmbio Korea Inc.: South Korea Biosidus: Colombia, ...
Abaloparatide-Patch patient assessment study results demonstrated high patient acceptability and self-administration accuracy over a 29-day period Levels of PINP, a biomarker for bone formation, after ...
WALTHAM, Mass., March 17, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing ...
(MENAFN- GlobeNewsWire - Nasdaq) itemprop="articleBody">-Post-hoc analysis suggests abaloparatide may be useful in the treatment of women with postmenopausal osteoporosis and concurrent osteoarthritis ...
Results showed that treatment with abaloparatide for 12 months resulted in significant increases in bone mineral density compared with placebo. The Food and Drug Administration (FDA) has approved ...
Full-Year 2019 TYMLOS U.S. net revenue exceeds financial guidance, surpassing $172M. TYMLOS exits 2019 with 52% market share in new patients1, on track for market leadership in 2020. Radius delivers ...
Radius Health Inc. won FDA approval, albeit mildly delayed, of injected Tymlos (abaloparatide) for postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic ...
Please provide your email address to receive an email when new articles are posted on . The FDA today approved an abaloparatide injection for the treatment of postmenopausal women with osteoporosis at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results